SARomics Biostructures AB and Vipergen ApS announced today a strategic partnership with the goal to offer enhanced hit and lead identification services based on their complementary technology platforms. By combining Vipergen’s DEL screening technologies with SARomics structural biology capabilities, the companies will enhance their drug discovery services by offering expedited hit identification and lead generation.
Vipergen’s high-fidelity DNA encoded library (DEL) screening technologies enable the identification of novel hit compounds by screening 500+ million drug-like molecules in a single tube or in living cells. Structural information involving detailed information about binding sites and binding poses of identified compounds can rapidly be generated by utilizing SARomics Biostructures structural biology capabilities. This combined information will greatly enhance and accelerate subsequent lead generation of identified hit compounds.
“The collaboration with Vipergen will leverage hit identification and lead generation towards challenging targets and accelerate the discovery of novel therapies” commented Björn Walse, Chief Executive Officer of SARomics.
“Vipergen is pleased to enter into a strategic collaboration with SARomics, a recognized leader in the structural biology field whose high-quality proteins meet all requirements for successful DEL screens,” said Nils Hansen, Chief Executive Officer of Vipergen. “We are excited to leverage our collaboration with SARomics to facilitate even better outcomes for Vipergen’s drug discovery clients.”
About SARomics Biostructures AB
SARomics Biostructures, Lund, Sweden provides structural biology and structure-based drug design services to biotech, pharmaceutical, and academic organizations. SARomics has built a global reputation for its structural biology skills and is currently supporting clients in North America, Europe and Japan to pursue their drug discovery objectives. For more information, please visit www.saromics.com.
About Vipergen ApS
Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the USA, EU, and Japan. For more details about Vipergen and the YoctoReactor® (yR), Binder Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms, please visit www.vipergen.com.
For additional information please contact:
Dr. Björn Walse, CEO
SARomics Biostructures AB
sales@saromics.com
Dr. Nils Jakob Vest Hansen, CEO
Vipergen ApS
info@vipergen.com
